This analysis was conducted for all cancers combined and then repeated for breast, prostate, and lung cancers.
When all analyses were repeated using breast cancer data from each of just one of the three sources (self-report, medical records, cancer register), the results were unchanged.
In this context, CTC phenotyping may serve as a "liquid biopsy" that is easily performed and repeated during breast cancer treatment and is a promising aid in guiding treatment decisions.
In an exploratory attempt to increase the available sample size and thus the study power of this study, the above analysis was repeated using breast cancer cases as well as the healthy controls from these cancer studies.
When all analyses were repeated using breast cancer data from each of just one of the three sources (cancer register, general practice medical records, self-report), the results were unchanged.
In the case of artifacts or strong enhancement of background glandular tissue in women not examined in the best phase of the menstrual cycle or with unexpected other hormonal influences, a repeat breast MRI can be required.
One of these women initially had a benign breast biopsy but was subsequently noted to have ductal carcinoma in situ (DCIS) on a follow-up repeat breast biopsy six months later done as part of an increased surveillance plan as determined by her physician.
Approximately 120 distinct missense variants have so far been uncovered within the BRCA1 BRCT repeats through breast cancer screening.
The analysis was initially conducted based upon a priori categorizations of nonexclusive and exclusive breast-feeding ≥2 weeks versus breast-feeding <2 weeks and was repeated for nonexclusive breast-feeding ≥3 months versus breast-feeding <3 months in which these data or similar were available.
